CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analog, cagrilintide. Also Read: Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company On Sunday, The New England Journal of Medicine ...